Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

Posts Tagged ‘biosciences’

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Posted by fidest press agency su martedì, 19 marzo 2019

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 61,000 shares of Pulse Biosciences common stock to three new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on March 15, 2019.The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual’s entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c).The options have an exercise price of $18.12 per share, which is equal to the closing price of Pulse Biosciences common stock on March 15, 2019. The 61,000 shares underlying the option grants will vest and become exercisable as to 25% of the shares annually beginning on the first anniversary of the recipient’s start date, subject to the recipient’s continued employment with Pulse Biosciences on these vesting dates. The options are subject to the terms and conditions of the 2017 Inducement Equity Incentive Plan and the award agreements entered into with each recipient.

Posted in Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

Knopp Biosciences to Present at 2019 BIO CEO & Investor Conference

Posted by fidest press agency su venerdì, 1 febbraio 2019

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that the management will present and conduct face-to-face meetings at the 2019 BIO CEO & Investor Conference, to be held in New York, NY on February 11-12.
Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, February 12 at 11:15 a.m. Eastern Time.
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 development in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Castle Biosciences to Present at the 2018 Piper Jaffray Healthcare Conference

Posted by fidest press agency su venerdì, 23 novembre 2018

Castle Biosciences, Inc., a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced that Derek Maetzold, President and CEO, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28th, 2018 at 10:10 a.m. EST in New York City.Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about treatment and follow up care based on the individual molecular signature of the patient’s tumor. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq; and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq;, with programs in development for other underserved cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Quadrant Biosciences to Collaborate on Signature Study of Minocycline Treatment of Autism Spectrum Disorder

Posted by fidest press agency su sabato, 27 ottobre 2018

Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network (ATN) and its university research partners on research into the treatment of autism spectrum disorder (ASD). The ATN is a collaboration of Autism Speaks and some of the finest children’s hospitals and academic institutions in North America, specializing in multi-disciplinary medical care for children with autism. This Signature Study, including researchers from the Cincinnati Children’s Hospital Medical Center, University of Pittsburgh, and University of Missouri, is looking at the treatment of autism symptoms with the antibiotic minocycline. In addition to providing financial support for this important study, Quadrant Biosciences will be collecting salivary RNA data to further its work on epigenetic factors associated with ASD.Prompted by earlier studies, researchers at the Cincinnati Children’s Hospital Medical Center initiated a study looking at the effects of minocycline treatment on ASD symptoms.
Given these characteristics, animal researchers hypothesized that minocycline treatment would improve autism symptoms, and indeed this was the case. Researchers saw improvement in many classic autism symptoms such as aberrant social interaction, exploratory behavior, locomotion, and anxiety behaviors in various mouse models of ASD treated with minocycline. Additionally, trials in humans with Fragile X Syndrome-associated ASD have demonstrated improvement on the Clinical Global Impression Improvement subscale. These compelling results prompted the initiation of the present Autism Speaks ATN Signature Study.
The Autism Speaks ATN research also received support through the ATN’s role as the federally funded Autism Intervention Research Network for Physical Health. The clinical trial to begin later this year will involve a 24-subject, double-blind, placebo-controlled, four-week crossover study of minocycline in youths with ASD ages 12 to 22 years. The study aims to: 1) Determine if minocycline use will be associated with reduction in elevated EEG gamma power in persons with ASD compared to placebo; 2) assess the short-term safety and tolerability of minocycline in youths with ASD; and 3) better understand the efficacy and dosage of minocycline for the short-term treatment of memory, social gaze, psychophysical markers, attentional impairments, quality of life, and other concerns in adolescents with ASD.
The study includes well-regarded researchers in the autism field including Craig A. Erickson, M.D., Professor, Division of Child and Adolescent Psychiatry, and Logan Wink, Associate Professor, Cincinnati Children’s Hospital Medical Center; David Beversdorf, M.D., Professor of Neurology, Radiology, and Psychology, Thompson Center for Autism & Neurodevelopmental Disorders, University of Missouri; and Benjamin Handen, Ph.D., Professor of Psychiatry, Pediatrics, Psychology, and Education, University of Pittsburgh.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

John Amatruda, MD, and Philip Lambert, PhD, Join Life Biosciences

Posted by fidest press agency su venerdì, 19 ottobre 2018

Life Biosciences Inc. announced today the appointment of two renowned scientists to senior positions at the pioneering company. Dr. John Amatruda has been appointed president of Life Laboratories, which provides central management and resources for drug discovery and development across Life Biosciences and its Daughter companies. Philip Lambert, PhD, has been named senior vice president, discovery and laboratories at Life Biosciences. Dr. Amatruda is also a member of Life Biosciences’ Scientific Advisory Board.Life Biosciences is the first and largest company to address age-related decline (ARD) as a systemic breakdown of the body, rather than a series of isolated events and conditions. The two scientists will support all Life Biosciences’ Daughter companies, as they pursue their independent and collaborative research into the eight pathways of age-related decline.
“We are thrilled and privileged to have John and Phil on our team,” said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. “Their exceptional and celebrated experience in both drug discovery and company-building will make them invaluable contributors to our mission.”Throughout his 26-year career in drug research and development, Dr. Amatruda has produced drugs that treat diabetes and cardiovascular disease. In addition to tenures as a professor at Yale University School of Medicine and The University of Rochester School of Medicine, he co-founded the biotech company CohBar, served on numerous scientific advisory panels and boards of directors and was a Vice President at Bayer Corp. and a Senior Vice President at Merck Pharmaceuticals.Dr. Lambert brings more than 25 years of experience in drug discovery and development to his role at Life Biosciences, as well as remarkable expertise in building companies and providing efficient and predictive preclinical drug discovery. Dr. Lambert comes to Life Biosciences from Charles River Laboratories where he was Head of Discovery Labs. Previously, Dr. Lambert co-founded and was Chief Scientific Officer at VivoPath, a contract research organization providing drug discovery solutions to the pharmaceutical and biotechnology community. Dr. Lambert brings a diverse perspective to his role at Life having held positions in biotechnology, large pharmaceutical companies, a non-profit, and contract research organizations.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Agilent to Expand Portfolio and Capabilities in Cell Analysis with Acquisition of ACEA Biosciences

Posted by fidest press agency su giovedì, 27 settembre 2018

Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250 million in cash.
“Expanding our cell analysis footprint is a key strategic growth initiative,” said Jacob Thaysen, president of Agilent’s Life Sciences and Applied Markets Group. “Innovative approaches to cell analysis are driving market demand and leading to a better understanding of diseases and the discovery of potential therapeutics.”Since its inception in 2002, ACEA has launched two ground-breaking, highly differentiated platforms. ACEA is revolutionizing the field of flow cytometry with its high-performance, customizable line of NovoCyte® benchtop flow cytometers. ACEA’s xCELLigence® instruments enable label-free, real-time monitoring of cell growth, cell function, and cellular responses to a variety of treatments, providing scientists information-rich cellular assays.ACEA also has a CFDA approved and CE-IVD labelled cytometer configuration. ACEA’s clinical flow cytometer, currently commercialized primarily in China, brings a unique opportunity with Agilent’s Reagent Partnership business within Agilent’s Diagnostics and Genomics Group which provides reagents for flow cytometry.ACEA instruments are used worldwide in both academia and industry across a wide range of life science applications from basic research to clinical diagnostics including preclinical drug discovery and development, toxicology & safety pharmacology, and various disease studies.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference

Posted by fidest press agency su domenica, 5 agosto 2018

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 2:30 pm ET at the Parker New York, in New York City, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is being evaluated in combination with other agents in multiple tumor types in a Phase 1/1b program, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and will be tested in combination with Arcus’s other product candidates. Arcus’s other programs include an anti-TIGIT antibody AB154, which is in a phase 1 program, and a small molecule inhibitor of CD73 AB680, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Logic Biosciences Announces International Award for LBS-101 Program

Posted by fidest press agency su giovedì, 2 agosto 2018

Logic Biosciences, Inc., a development-stage pharmaceutical company, today announced that its lead product candidate, LBS-101, has been recognized with an Innovation in Oral Care Award from the International Association for Dental Research (IADR). LBS-101 is a long-acting topical formulation of a novel salt of bupivacaine, being developed for oral pain from mouth ulcers (oral mucositis) secondary to chemotherapy or radiation therapy for cancer. The award also includes research funding to the University of Connecticut (UConn), to advance the drug development program. This funding is supported by GlaxoSmithKline, through an unrestricted grant to the IADR. Awardees are selected by a scientific review panel of the IADR. The award was given at the IADR conference held in London, England from July 25-28, 2018.Mahesh Kandula, CEO of Logic Biosciences, stated, “We are excited about this international recognition for the LBS-101 program. It is noteworthy that the panel of distinguished judges saw the scientific value of our approach and selected this program for this honor. Since our novel drug is based on a known pharmaceutical agent, we expect to have relatively lower drug development costs and a faster path to approval.”Rajesh Lalla, DDS, PhD, Associate Professor at UConn and Chief Scientific Advisor of Logic Biosciences, stated, “Oral Mucositis causes severe pain that often requires systemic opioids, which have significant side-effects. The development of a locally acting anesthetic that is more potent and longer-acting than the current standard of care would be of great value to our patients and could reduce the need for systemic opioids.”This program had previously also received funding from the SPARK Technology Commercialization Fund at UConn, where a novel drug formulation has been developed in collaboration with Distinguished Professor Diane Burgess of the UConn School of Pharmacy. A Phase I clinical study is being planned, tentatively for 2019.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights

Posted by fidest press agency su domenica, 15 luglio 2018

Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, today announced that the Company will report second quarter 2018 operational highlights and financial results on Tuesday, July 31, 2018. Pulse Biosciences management will host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Pulse Biosciences is a publicly listed clinical stage electroceutical company pursuing multiple clinical applications of its proprietary Nano-Pulse Stimulation technology. Nano-Pulse Stimulation (NPS) is a non-thermal, precise, focal tissue treatment technology comprised of nanosecond (billionth of a second) range pulsed electric fields that directly affect the cell membrane and intracellular structures and initiates cell death in treated cells. The initiation of cell death by NPS results in a minimal inflammatory response, which improves healing outcomes and supports the replacement of treated tissue cells with healthy tissue cells. NPS’ unique mechanism of action to initiate cell death has the potential to significantly benefit patients for multiple medical applications in dermatology, immune-oncology, and in other unique tissue targets. In cancerous lesions, NPS has been shown in preclinical models to induce immunogenic cell death (ICD), which exposes the unique antigens of the treated cells to the immune system and enrolls immune system cells, such as cytotoxic T-cells to mount an adaptive immune response. More information is available at

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting

Posted by fidest press agency su venerdì, 1 dicembre 2017

University of South Alabama (USA)Development of Microbiome Therapeutics for Cancer Immunotherapy. Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune-mediated and infectious diseases based on rationally designed consortia of human microbiome-derived bacteria, today announced new translational medicine collaborations in cancer immunotherapy with Leiden University Medical Center and the University of South Alabama (USA) Mitchell Cancer Institute. The Company also today announced the expansion of its translational medicine collaboration in cancer immunotherapy with NYU Langone Health and its Perlmutter Cancer Center. Researchers at these institutions have been collaborating with Vedanta Biosciences to analyze microbiome clinical data from interventional checkpoint inhibitor studies to identify microbiome signatures associated with response to immunotherapy and key mechanisms through which the gut microbiota modulate immunotherapeutic responses.“Data from our ongoing clinical collaborations in melanoma show that gut bacteria signatures could help determine if a cancer immunotherapy will work,” said Bruce Roberts, Ph.D., Chief Scientific Officer of Vedanta Biosciences. “We’re pleased to expand our research collaborations into others forms of cancer, with the ultimate goal of identifying ways to change the microbiome to increase the proportion of patients and types of cancer patients who respond to immunotherapies.”Under the agreement with Leiden University Medical Center, Vedanta Biosciences will work in collaboration with Ellen Kapiteijn, M.D., Ph.D., and Ed Kuijper, M.D., Ph.D., to understand the role of the microbiome in immunotherapeutic responses against a variety of cancers, including melanoma, head and neck, and bladder. The new collaboration with the USA Mitchell Cancer Center, led by Art Frankel, M.D., will analyze associations between the gut microbiome and responses to checkpoint inhibitor treatment in melanoma and cancers of the bladder and kidneys. Building on the existing translational work with NYU Langone in melanoma led by Jeffrey S. Weber, M.D., Ph.D., and Melissa Wilson, M.D., Ph.D., the expanded agreement adds collaborations in bladder cancer and lung cancer, led, respectively, by Arjun V. Balar, M.D., and Leena Gandhi, M.D., Ph.D.Vedanta Biosciences’ immuno-oncology programs include lead product candidate, VE800, which has been shown in preclinical models to activate CD8+ T cells, a type of white blood cell that is the predominant effector in cancer immunotherapy, improve CD8+ T cell tumor infiltration, and improve survival in several cancer models in combination with checkpoint inhibitors. Vedanta anticipates filing an investigational new drug application (IND) for this candidate in 2018.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates

Posted by fidest press agency su giovedì, 2 novembre 2017

tumore metastatico1Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune and infectious diseases based on rationally designed consortia of human microbiome-derived bacteria, today announced that it has exclusively sub-licensed key intellectual property from JSR Corporation to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics. These live biotherapeutics have been shown to activate CD8+ T cells, a type of white blood cell that is the predominant effector in cancer immunotherapy. The sub-licensed intellectual property is based on the pioneering research of Dr. Kenya Honda, Professor, of Keio University School of Medicine and his collaborators in the University of Tokyo in Japan. An IND filing for the lead product candidate is planned in 2018.“Dr. Honda’s research suggests an entirely new approach to cancer immunotherapy harnessing the human microbiome, which has the potential to significantly enhance the effectiveness of cancer therapies,” said Bernat Olle, PhD, Chief Executive Officer of Vedanta Biosciences. “We are actively developing product candidates containing defined bacterial consortia that activate CD8+ T cells and stimulate the immune system to fight cancer alone and in combination with checkpoint inhibitors. This license to additional intellectual property from Dr. Honda’s institution further strengthens Vedanta’s leading IP position in the microbiome field.” In validated pre-clinical models of cancer, Vedanta’s orally administered product candidates containing defined bacterial consortia induced CD8+ T cells, potentiating the immune system’s attack of tumor cells. The tumor fighting effects of a variety of checkpoint inhibitors were significantly amplified when combined with the bacterial consortia, suggesting a potentially novel approach for combination cancer immunotherapy.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders

Posted by fidest press agency su domenica, 27 agosto 2017

Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its 2017 Annual Meeting of Stockholders (“Annual Meeting”), scheduled for Wednesday, August 16, 2017, was convened and dismissed, without any business being conducted, due to lack of the requisite quorum. The Annual Meeting has now been rescheduled for Thursday, October 5, 2017 at a place and time still to be determined by the Board of Directors, in order to allow additional time for stockholders to receive new proxy materials and vote on the updated proposals to be set forth in Xenetic’s definitive proxy statement on Schedule 14A, which will be amended or supplemented to include the updated proposals. Such amendment or supplement to the proxy statement will be filed with the Securities and Exchange Commission and mailed to the Company’s stockholders as soon as reasonably practicable. A new record date for the Annual Meeting has yet to be determined but will be included in the updated proxy materials, along with the time and location of the Annual Meeting.The Company strongly advises all of its stockholders to read the proxy statement (including any amendments or supplements thereto, once they become available) and other proxy materials relating to the Annual Meeting because they contain important information. Such proxy materials will be available at no charge on the Securities and Exchange Commission’s website at In addition, copies of the proxy statement (including any amendments or supplements thereto) and other documents will be available free of charge as soon as reasonably practicable by accessing the Company’s website at or by contacting the Company’s Corporate Secretary at 781-778-7720 or by mail to Corporate Secretary, Xenetic Biosciences, Inc., 99 Hayden Ave., Ste. 230, Lexington, MA 02421.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »